Machine Learning and Augmented Intelligence Enables Prognosis of Type 2 Diabetes Prior to Clinical Manifestation
February 1, 2024
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
A Historical Journey through Pharmacology, Total Synthesis, and Evolution Towards Iboga Alkaloid Analogs
AbstractIbogaine, a powerful psychedelic, has been used throughout the world for much of human history. Its diverse usage has led to a uniq…
Read more
The Multi-Omics Profiling of Early-Passage Mesenchymal Stem Cell Exosomes Reveals Potential Targets for Attenuating Diabetic Inflammatory Pathophysiology
Read more
Operon™ Platform–Enabled for Cardiometabolic Biomarker Screening and Precision Treatment Strategies: A Type 2 Diabetes–Centered Review with Cardiovascular Extension
Operon™ Platform–Enabled for Cardiometabolic Biomarker Screening and Precision Treatment Strategies: A Type 2 Diabetes–Centered Review with…
Read more